Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft - PubMed (original) (raw)
Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft
C Palma et al. Br J Cancer. 2000 Jan.
Abstract
Astrocytes harbour functional receptors to many neurotransmitters, including substance P (SP), an undecapeptide belonging to the tachykinin family of peptide transmitters. SP activates malignant glial cells to induce cytokine release and proliferation, both responses being relevant for tumour progression. In tumours developed in nude mice transplanted subcutaneously (s.c.) to U373 MG human glioma cells, the presence of SP was observed at immunohistochemistry. Although the administration of exogenous SP did not significantly affect the size or development of U373 MG xenograft, a role of SP in supporting glioma progression in vivo was highlighted by the tumour growth inhibition induced by highly specific and selective human tachykinin NK1 receptor antagonists (MEN 11467 and MEN 11149). The anti-tumour activity of MEN 11467 was observed both with s.c. or intravenous treatments and was partially reverted by the concomitant administration of exogenous SP. Doxorubicin did not show any activity in controlling U373 MG growth in this in vivo model. A novel therapeutic approach to treat malignant gliomas with tachykinin NK1 receptor antagonists is suggested by these findings.
Similar articles
- Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors.
Palma C, Nardelli F, Manzini S, Maggi CA. Palma C, et al. Br J Cancer. 1999 Jan;79(2):236-43. doi: 10.1038/sj.bjc.6690039. Br J Cancer. 1999. PMID: 9888463 Free PMC article. - Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
Cirillo R, Astolfi M, Conte B, Lopez G, Parlani M, Sacco G, Terracciano R, Fincham CI, Sisto A, Evangelista S, Maggi CA, Manzini S. Cirillo R, et al. Neuropeptides. 2001 Jun-Aug;35(3-4):137-47. doi: 10.1054/npep.2001.0855. Neuropeptides. 2001. PMID: 11884203 - The role of tachykinins via NK1 receptors in progression of human gliomas.
Palma C, Maggi CA. Palma C, et al. Life Sci. 2000;67(9):985-1001. doi: 10.1016/s0024-3205(00)00692-5. Life Sci. 2000. PMID: 10954033 Review. - Correlation between binding characteristics and functional antagonism in human glioma cells by tachykinin NK1 receptor antagonists.
Palma C, Nardelli F, Manzini S. Palma C, et al. Eur J Pharmacol. 1999 Jun 25;374(3):435-43. doi: 10.1016/s0014-2999(99)00334-9. Eur J Pharmacol. 1999. PMID: 10422788 - Substance P and its receptors -- a potential target for novel medicines in malignant brain tumour therapies (mini-review).
Łazarczyk M, Matyja E, Lipkowski A. Łazarczyk M, et al. Folia Neuropathol. 2007;45(3):99-107. Folia Neuropathol. 2007. PMID: 17849359 Review.
Cited by
- The Effect of SP/NK1R on the Expression and Activity of Catalase and Superoxide Dismutase in Glioblastoma Cancer Cells.
Korfi F, Javid H, Assaran Darban R, Hashemy SI. Korfi F, et al. Biochem Res Int. 2021 Apr 21;2021:6620708. doi: 10.1155/2021/6620708. eCollection 2021. Biochem Res Int. 2021. PMID: 33976938 Free PMC article. - The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer.
Rosso M, Muñoz M, Berger M. Rosso M, et al. ScientificWorldJournal. 2012;2012:381434. doi: 10.1100/2012/381434. Epub 2012 Apr 1. ScientificWorldJournal. 2012. PMID: 22545017 Free PMC article. Review. - MiR-34b/c-5p and the neurokinin-1 receptor regulate breast cancer cell proliferation and apoptosis.
Zhang L, Wang L, Dong D, Wang Z, Ji W, Yu M, Zhang F, Niu R, Zhou Y. Zhang L, et al. Cell Prolif. 2019 Jan;52(1):e12527. doi: 10.1111/cpr.12527. Epub 2018 Oct 17. Cell Prolif. 2019. PMID: 30334298 Free PMC article. - The NK-1 Receptor Antagonist L-732,138 Induces Apoptosis and Counteracts Substance P-Related Mitogenesis in Human Melanoma Cell Lines.
Muñoz M, Rosso M, González-Ortega A, Coveñas R. Muñoz M, et al. Cancers (Basel). 2010 Apr 20;2(2):611-23. doi: 10.3390/cancers2020611. Cancers (Basel). 2010. PMID: 24281084 Free PMC article. - Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood-brain barrier during extravasation and brain invasion.
Lewis KM, Harford-Wright E, Vink R, Nimmo AJ, Ghabriel MN. Lewis KM, et al. Clin Exp Metastasis. 2013 Jan;30(1):1-12. doi: 10.1007/s10585-012-9487-z. Epub 2012 May 19. Clin Exp Metastasis. 2013. PMID: 22610781
References
- J Neuroimmunol. 1995 Jun;59(1-2):155-63 - PubMed
- Int J Cancer. 1995 Jun 9;61(6):832-9 - PubMed
- J Neurochem. 1996 Nov;67(5):1813-20 - PubMed
- Cancer Res. 1996 Nov 1;56(21):4983-91 - PubMed
- Glia. 1997 Oct;21(2):183-93 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources